28.08.2022, 5293 Zeichen

Marinomed: Marinomed Biotech AG, an Austrian science-based biotech company with globally marketed therapeutics, reported today financial results for the first half of the financial year 2022. With a continued high demand for Carragelose, Marinomed reports its strongest second quarter to date. Revenues for the first half 2022 increased to Euro 4.9 mn compared to the previous year (H1 2021: Euro 3.2 m; +52 %) with sustained high sales of the virus blocker Carragelose. R&D expenses have decreased to Euro 3.3 mn compared to the previous year (H1 2021: Euro 4.3 mn, -22 %). This trend was already visible in Q1 2022 and is mostly due to the reduced clinical development activities compared to the last year. With the new augmented strategy 2025, R&D is now focusing on laboratory studies, which are less cost intensive. As Marinomed advances the development of its Rx product candidates into formal preclinical and later, clinical development, and together with a planned expansion of its pipeline, R&D expenses are expected to increase again in the coming years. The operating result (EBIT) was Euro -2.5 mn, an improvement over the same period in the past year (H1 2021: Euro -3.6 mn; +31 %). Net loss for the period was Euro 3.8 mn compared to Euro 4.4 mn in H1 2021, in line with the company’s business plan. Marinomed confirms its financial outlook for the fiscal year: The Company expects continued growth of Carragelose revenues and a slight increase in R&D expenses, and consequently an operating loss for 2022. Marinomed plans to reach operating profitability in the medium term.
Marinomed Biotech: weekly performance: 2.58%

UBM: Real estate developer UBM generated Total Output of Euro 206.2 mn in the first half of 2022 (H1/21: Euro 237.3 mn). EBT amounted to Euro 16.1 mn and was lower than the comparable prior year value of Euro 35.7 mn. Net profit of Euro 15.8 mn represented a decline compared with the record half year in 2021 (H1/21: Euro 27.5 mn). Earnings per share rose from Euro 0.32 in the first quarter of 2022 to Euro 1.49 for the reporting period. According to the company, signs indicate that the “perfect storm“ will hit the real estate market in the course of this year. UBM sees itself well positioned for this difficult phase due to its focus on residential and office properties combined with the green. smart. and more. strategy. The demand for housing and new offices will remain high, especially in major cities like Vienna, Munich, Frankfurt or Prague, where most of the projects are located. A further driver for UBM is the growing demand for energy-efficient, ESG-compliant buildings to meet European climate goals. Based on the development of earnings in the first half of 2022 and on the current market situation, UBM is issuing an operating guidance of Euro 38 mn to Euro 42 mn for EBT in the 2022 financial year. This outlook is dependent on how and where the “perfect storm“ will hit the market in the coming months.
UBM: weekly performance: -3.53%

EVN: Revenue recorded by the utility company EVN Group rose by 64.6% to Euro 2,943.7 m in the first three quarters of 2021/22 and was driven by a number of individual effects. In South East Europe, the sharp rise in electricity prices led to double-digit growth in the energy business. In Austria, the network tariff increases set by E-Control as of 1 January 2021 and 1 January 2022 had a positive influence on network revenue. Other important impulses were provided by volume and price effects from renewable electricity generation, price adjustments by EVN Wärme, higher revenue from natural gas trading and positive valuation effects from hedges. In addition, an increase in the use of the Theiss power plant by the Austrian transmission network operator for network stabilisation offset the absence of revenue from the Walsum 10 power plant following the sale of EVN’s investment and the termination of electricity purchases from this source. Growth was also recorded in the international project business. EBITDA recorded by the EVN Group fell by 11.8% year-on-year to Euro 578.1 mn in the first three quarters of 2021/22. Scheduled depreciation and amortisation, including the effects of impairment testing, declined to Euro –51.2 mn (previous year: Euro –111.6 mn), chiefly due to different effects from impairment testing. In the second quarter of 2021/22, a change in the Group’s risk and earnings expectations for future projects based on the global distortions had already led to the recognition of an impairment loss to goodwill in the international project business (Euro 52.9m) and to the residual carrying amount of the two sludge-fired combined heat and power plants in Moscow (Euro 4.4 mn). These impairment losses were contrasted by a revaluation of Euro 6.4 mn to the Kavarna wind park in Bulgaria during the first quarter of 2021/22 to reflect the changed regula- tory conditions in combination with an increase in electricity prices. In the previous year, the takeover of an additional electricty procurement right resulted in the recognition of impairment losses totalling Euro 113.1 mn to the Walsum 10 power plant. In total, EBIT declined by 0.6% to Euro 290.2 mn.
EVN: weekly performance: -4.27%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (25/08/2022)

Christian Drastil: Wiener Börse Plausch

SportWoche Podcast #121: Martin Wechtl, ein Fanboy mit u.a. laola1- und Admira Wacker-Background

Bildnachweis

Aktien auf dem Radar:Immofinanz, CA Immo, DO&CO, Warimpex, Flughafen Wien, Marinomed Biotech, VIG, Porr, EVN, RBI, Uniqa, Telekom Austria, AT&S, Rosenbauer, ams-Osram, FACC, Stadlauer Malzfabrik AG, Wolford, Zumtobel, Oberbank AG Stamm, BKS Bank Stamm, Kapsch TrafficCom, Agrana, Amag, Erste Group, Österreichische Post, Polytec Group, S Immo, Wienerberger, Rheinmetall, SAP.

---